Search the Newsreel

SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales

Jeremy Hayden, an insider at Sight Sciences, Inc. (SGHT), has filed a Form 144 detailing planned sales of common stock through Fidelity Brokerage Services LLC. The filing also reports prior restricted stock vestings from January 2024, March 2024, and a scheduled vesting in January …

Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates

SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale

SGHT insider Jeremy Hayden plans to sell 20,918 shares of common stock, valued at approximately $165,878.62, through Fidelity Brokerage Services on August 11, 2026. This sale relates to previously scheduled restricted stock vesting events. Hayden also reported a prior sale of 12,733 shares for …

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com

Sight Sciences (NASDAQ:SGHT) has announced the appointment of Kashif Rashid as its new chief legal officer and corporate secretary, effective Monday. Rashid brings extensive legal leadership experience from previous roles at Nevro Corp. and other companies. Concurrently, Jeremy Hayden will step down from the …

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down

Sight Sciences, Inc. has announced the appointment of Kashif Rashid as its new chief legal officer and corporate secretary, effective immediately. Rashid brings extensive experience from previous legal leadership roles at several companies, and his compensation package includes an annual base salary of $450,000, …

Form 8K Sight Sciences Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Sight Sciences Inc. for August 10, 2026. It is a brief, standard financial news update provided by Investing.com, indicating a regulatory filing has occurred for the company.

Sight Sciences (SGHT) Q2 2026 Earnings: Narrower Loss Drives 5.36% Stock Rally - Product Revenue Analysis

Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen

Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside

The average 12-month price target for Sight Sciences, Inc. (SGHT) stock has been raised from $8.4 to $8.6 by 5 analysts, with a range of $6 to $12 per share. This new target suggests a potential upside of approximately 55% based on the August …

Sight Sciences Inc (SGHT) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and Raised ...

Sight Sciences Inc. (SGHT) reported strong Q2 2026 earnings, featuring a 20% year-over-year increase in total revenue to $23.4 million, marking its strongest quarterly growth in three years. The company also saw significant improvement in its interventional dry eye revenue, which nearly doubled, and …

UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock

UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating

UBS has increased its price target for Sight Sciences (SGHT) to $8 from $7, while reiterating a Buy rating on the stock. This adjustment follows Sight Sciences' Q2 2026 earnings call and news of FDA 510(k) clearance for its OMNI Ultra Surgical System. The …

Sight Sciences, Inc. Q2 2026: Revenue $23.39M, EPS $(0.08) — 10-Q Summary

Sight Sciences, Inc. (SGHT) reported strong second-quarter 2026 results, with revenue increasing to $23.39 million, a 19.5% year-over-year growth. The company also significantly reduced its net loss, improving diluted loss per share to $(0.08) from $(0.23) in the prior year. This financial improvement was …

Sight Sciences earnings beat by $0.07, revenue topped estimates

Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance

Sight Sciences, Inc. reported strong financial results for Q2 2026, with revenue increasing by 20 percent to $23.4 million and a significant reduction in net loss. The company raised its full-year 2026 revenue guidance to $88 million to $92 million, driven by growth in …

Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS

Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall

Sight Sciences reported a strong Q2 2026 with revenue increasing 20% year-over-year to $23.4 million, its fastest growth since 2023, and a narrowed net loss. The company raised its full-year 2026 revenue guidance to $88 million-$92 million and lowered adjusted operating expense guidance. Despite …

Sight Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Sight Sciences, Inc. has released its earnings summary for the quarter that ended on June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance during this period.

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) reported a Q2 loss of $0.08 per share, outperforming the Zacks Consensus Estimate of a $0.15 loss, and significantly improving from a $0.23 loss a year ago. The company also surpassed revenue estimates, posting $23.39 million against an anticipated $21.75 …

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences reported strong second-quarter 2026 financial results, with total revenue increasing by 20% year-over-year to $23.4 million, driven by significant growth in Interventional Dry Eye revenue (704% increase). The company raised its full-year 2026 revenue guidance to $88 million to $92 million and …

Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com

Aetna Inc. has updated its Glaucoma Surgery Policy for commercial plans to recognize Sight Sciences' OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma. This coverage, retroactive to July 14, 2026, applies to approximately 25 million Aetna commercial …

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Sight Sciences announced that Aetna, Inc. has updated its Glaucoma Surgery Policy to recognize the OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma, given specific clinical criteria are met. This decision expands coverage for implant-free, minimally invasive …

Sight Sciences (NASDAQ: SGHT) lifts 2026 outlook after 20% Q2 growth

FDA Clears Sight Sciences’ OMNI Ultra Surgical System

Sight Sciences has received FDA 510(k) clearance for its OMNI Ultra surgical system, designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This implant-free MIGS device is the first to perform circumferential canaloplasty in a single pass and features TruSync Plus …

Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences’ Record Dry Eye Revenue Jumps 704% to $2.7M

FDA clears Sight Sciences’ OMNI Ultra glaucoma device By Investing.com

Sight Sciences Inc. (NASDAQ:SGHT) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its OMNI Ultra Surgical System. This device is designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma through canaloplasty followed by trabeculotomy. The …

Sight Sciences' FDA-cleared glaucoma system leaves no implant behind

Sight Sciences (Nasdaq: SGHT) has received FDA 510(k) clearance for its OMNI Ultra Surgical System, designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This system is notable as the first FDA-cleared MIGS device for single-pass circumferential canaloplasty and is implant-free, …

Sight Sciences Announces FDA 510(k) Clearance of OMNI Ultra Surgical System for Primary Open-Angle Glaucoma

Sight Sciences has received FDA 510(k) clearance for its OMNI Ultra surgical system, designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This implant-free MIGS device is the first to perform circumferential canaloplasty in a single pass and features TruSync Plus …

Earnings To Watch: Sight Sciences Inc (SGHT) Q2 2026 -- GF Value Sees 9% Downside

Sight Sciences, Inc. Revenue Breakdown – NASDAQ:SGHT

Sight Sciences, Inc. (NASDAQ: SGHT) generated $77.36 million USD in revenue last year, with its Interventional Glaucoma segment contributing the majority at $75.72 million USD. This represents a slight decrease from the previous year's $75.90 million for the segment. The United States was the …

Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Wednesday